Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 28, 2022

Primary Completion Date

December 31, 2027

Study Completion Date

June 30, 2028

Conditions
Hepatocellular Carcinoma Non-resectable
Interventions
COMBINATION_PRODUCT

Fluorine-18 fluorocholine

18F-fluorocholine is a radiopharmaceutical imaging agent intended for use only with positron emission tomography (PET) imaging. PET with in-line computed tomography imaging of the torso will be performed following intravenous administration of a single unit dose of this investigational new drug.

Trial Locations (1)

96813

RECRUITING

The Queen's Medical Center, Honolulu

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Queen's Medical Center

OTHER